Beyond Air Inc

NASDAQ XAIR

Data sourced from iex and EODHD
Download Data

Beyond Air Inc Net Debt for the year ending March 31, 2023: USD 51.65 M

Beyond Air Inc Net Debt is USD 51.65 M for the year ending March 31, 2023, a -42.38% change year over year. Net Debt is the difference between a company's total debt and its cash and cash equivalents.
  • Beyond Air Inc Net Debt for the year ending March 31, 2022 was USD 89.65 M, a 125.40% change year over year.
  • Beyond Air Inc Net Debt for the year ending March 31, 2021 was USD 39.77 M, a 61.86% change year over year.
  • Beyond Air Inc Net Debt for the year ending March 31, 2020 was USD 24.57 M.
NASDAQ: XAIR

Beyond Air Inc

CEO Mr. Steven Adam Lisi
IPO Date Sept. 22, 2017
Location United States
Headquarters 900 Stewart Avenue, Garden City, NY, United States, 11530
Employees 98
Sector Healthcare
Industry Medical devices
Description

Beyond Air, Inc. operates as a commercial-stage medical device and biopharmaceutical company in the United States. The company engages in the development of LungFit platform, a nitric oxide generator and delivery system. It offers LungFit PH for the treatment of persistent pulmonary hypertension of the newborn. The company is also developing LungFit PRO for the treatment of viral lung infections, such as community-acquired viral pneumonia, including COVID-19, as well as bronchiolitis in hospitalized patients; and LungFit GO for the treatment of nontuberculous mycobacteria. The company was formerly known as AIT Therapeutics, Inc. and changed its name to Beyond Air, Inc. in June 2019. Beyond Air, Inc. is based in Garden City, New York.

Similar companies

CLPT

Clearpoint Neuro Inc

NA

NA

TELA

Tela Bio Inc

NA

NA

StockViz Staff

September 16, 2024

Any question? Send us an email